Biobanking in LMIC settings for infectious diseases: Challenges and enablers [0.03%]
低收入和中等收入国家的传染病生物样本库建设：挑战与机遇
Sameera Ezzat,Ruzica Biga,Zisis Kozlakidis
Sameera Ezzat
Biobanking facilities are well established in high-income settings, where substantial funding has been invested in infrastructure. In contrast, such facilities are much less developed in resource-restricted settings. However, low-and middle...
Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination [0.03%]
新冠病毒广泛接种初期S蛋白基因相对快速的进化速率
Jing Yang,Min Han,Liang Wang et al.
Jing Yang et al.
A series of stringent non-pharmacological and pharmacological interventions were implemented to contain the pandemic but the pandemic continues. Moreover, vaccination breakthrough infection and reinfection in convalescent coronavirus diseas...
Harmonizing the COVID-19 sample biobanks: Barriers and opportunities for standards, best practices and networks [0.03%]
新冠病毒样本生物库的标准化、最佳实践和网络建设的壁垒与机遇协调工作
Balwir Matharoo-Ball,Mbayame Diop,Zisis Kozlakidis
Balwir Matharoo-Ball
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the practice of infectious diseases biobanking, as well as existing challenges and opportunities. Thus, the future of infectious diseases biobanking in the post-pandemic era, ...
Characterization and determinant factors of critical illness and in-hospital mortality of COVID-19 patients: A retrospective cohort of 1,792 patients in Kenya [0.03%]
肯尼亚1792例新冠肺炎患者的重症及院内死亡的临床特征和影响因素：回顾性队列研究
Isinta M Elijah,Endawoke Amsalu,Xuening Jian et al.
Isinta M Elijah et al.
Limited data is available on the coronavirus disease 2019 (COVID-19), critical illness rate, and in-hospital mortality in the African setting. This study investigates determinants of critical illness and in-hospital mortality among COVID-19...
Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic [0.03%]
纳米技术在生物安全材料应用中的进展——对新冠肺炎疫情的重要响应
Rasmi V Morajkar,Akhil S Kumar,Rohan K Kunkalekar et al.
Rasmi V Morajkar et al.
The outbreak of coronavirus disease 2019 (COVID-19) has adversely affected the public domain causing unprecedented cases and high mortality across the globe. This has brought back the concept of biosafety into the spotlight to solve biosafe...
Access and benefit-sharing of the pathogenic microorganisms such as SARS-CoV-2 [0.03%]
获取和分享致病微生物（如SARS-CoV-2）的利益
Yalin Zhai,Geng Hong,Mengnan Jiang et al.
Yalin Zhai et al.
With the outbreak of coronavirus disease 2019 (COVID-19), it is essential to share pathogens and their data information safely, transparently, and timely. At the same time, it is also worth exploring how to share the benefits of using the p...
Zhaomin Feng,Shujuan Cui,Bing Lyu et al.
Zhaomin Feng et al.
At present, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread worldwide, which has emerged multiple variants and brought a threat to global public health. To analyze the genomic characteristics and variations of SARS-CoV-2...
Weijing Yuan,Xiaojing Dong,Lan Chen et al.
Weijing Yuan et al.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, generating new variants that pose a threat to global health; therefore, it is imperative to obtain safe and broad-spectrum antivirals against SARS-CoV-2 and i...
Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants [0.03%]
动物模型在比较当前及未来潜在新冠病毒变异毒株致病性中的应用研究
Zhe Ding,Tong Chen,Jiaming Lan et al.
Zhe Ding et al.
Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified during late 2019, the sustained spread of this pathogen within the human population has caused worldwide disruption with staggering infection rates and ...